1. Home
  2. CORT
  3. CORT News

Latest Corcept Therapeutics Incorporated (CORT) News on May 10, 2025

1 Small-Cap Stock Worth Your Attention and 2 to Question
CORT

StockStory

2 days ago

1 Small-Cap Stock Worth Your Attention and 2 to Question

Corcept Therapeutics price target lowered to $135 from $150 at Truist
CORT

TipRanks

2 days ago

Corcept Therapeutics price target lowered to $135 from $150 at Truist

CORT

Argus Research

3 days ago

CORT: Lowering target price to $78.00

CORT

Thomson Reuters StreetEvents

3 days ago

Q1 2025 Corcept Therapeutics Inc Earnings Call

Corcept Therapeutics (NasdaqCM:CORT) Reports US$21M Q1 Net Income Lowers EPS
CORT

Simply Wall St.

3 days ago

Corcept Therapeutics (NasdaqCM:CORT) Reports US$21M Q1 Net Income Lowers EPS

CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
CORT

Zacks

3 days ago

CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall

CORT

MT Newswires

4 days ago

Corcept Therapeutics Insider Sold Shares Worth $2,915,922, According to a Recent SEC Filing

CORT

MT Newswires

4 days ago

Corcept Therapeutics Insider Sold Shares Worth $2,842,769, According to a Recent SEC Filing

Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid ...
CORT

GuruFocus.com

4 days ago

Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid ...

Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates
CORT

Zacks

4 days ago

Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates

Corcept (NASDAQ:CORT) Misses Q1 Sales Targets, Stock Drops
CORT

StockStory

4 days ago

Corcept (NASDAQ:CORT) Misses Q1 Sales Targets, Stock Drops

CORT

MT Newswires

4 days ago

Corcept Therapeutics Q1 Earnings Decrease, Revenue Rises -- Shares Fall After Hours

CORT

Associated Press Finance

4 days ago

Corcept: Q1 Earnings Snapshot

CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CORT

Business Wire

4 days ago

CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Corcept Therapeutics (CORT): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential
CORT

Insider Monkey

5 days ago

Corcept Therapeutics (CORT): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential

Corcept (CORT) To Report Earnings Tomorrow: Here Is What To Expect
CORT

StockStory

6 days ago

Corcept (CORT) To Report Earnings Tomorrow: Here Is What To Expect

Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years?
CORT

Insider Monkey

9 days ago

Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years?

Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?
CORT

Zacks

10 days ago

Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL
CORT

Business Wire

11 days ago

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

3 Healthcare Stocks That Concern Us
CORT

StockStory

11 days ago

3 Healthcare Stocks That Concern Us

3 Growth Companies With High Insider Ownership Achieving 70% Earnings Growth
CORT

Simply Wall St.

16 days ago

3 Growth Companies With High Insider Ownership Achieving 70% Earnings Growth

Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
CORT

Insider Monkey

16 days ago

Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025
CORT

Business Wire

16 days ago

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

CORT

Argus Research

17 days ago

CORT: Lowering target price to $71.00

Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes
CORT

Business Wire

19 days ago

Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

CORT

Argus Research

24 days ago

CORT: Lowering target price to $76.00

Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter
CORT

Simply Wall St.

a month ago

Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter

CORT

Argus Research

a month ago

CORT: Lowering target price to $78.00

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
CORT

Business Wire

a month ago

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

CORT

MT Newswires

a month ago

Corcept Therapeutics Insider Sold Shares Worth $10,121,594, According to a Recent SEC Filing

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More
CORT

Zacks

a month ago

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?
CORT

Zacks

a month ago

Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?

CORT

Argus Research

a month ago

CORT: Raising target price to $120.00

Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz
CORT

TipRanks

a month ago

Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz

CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
CORT

Zacks

a month ago

CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal

Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?
CORT

Zacks

a month ago

Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?

Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday?
CORT

Insider Monkey

a month ago

Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday?

Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement
CORT

Clinical Trials Arena

a month ago

Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement

CORT

MT Newswires

a month ago

Equity Markets Mixed Ahead of Tariff Announcements

Why Is Corcept (CORT) Stock Soaring Today
CORT

StockStory

a month ago

Why Is Corcept (CORT) Stock Soaring Today

Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip
CORT

Simply Wall St.

a month ago

Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip

CORT

MT Newswires

a month ago

Top Midday Gainers

NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute
CORT

Yahoo Finance Video

a month ago

NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute

CORT

MT Newswires

a month ago

Piper Sandler Raises Corcept Therapeutics' Price Target to $128 From $78, Maintains Overweight Rating

CORT

MT Newswires

a month ago

Sector Update: Health Care Stocks Fall Pre-Bell Monday

CORT

MT Newswires

a month ago

Sector Update: Health Care

CORT

MT Newswires

a month ago

Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
CORT

Business Wire

a month ago

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?
CORT

Zacks

a month ago

Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?

3 Reasons to Sell CORT and 1 Stock to Buy Instead
CORT

StockStory

a month ago

3 Reasons to Sell CORT and 1 Stock to Buy Instead

CORT

Argus Research

a month ago

CORT: Raising target price to $76.00

Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?
CORT

Zacks

2 months ago

Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?

3 Growth Stocks in Hot Water
CORT

StockStory

2 months ago

3 Growth Stocks in Hot Water

1 Small-Cap Stock on Our Buy List and 2 to Avoid
CORT

StockStory

2 months ago

1 Small-Cap Stock on Our Buy List and 2 to Avoid

Top Growth Companies With Significant Insider Ownership
CORT

Simply Wall St.

2 months ago

Top Growth Companies With Significant Insider Ownership

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
CORT

Business Wire

2 months ago

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Corcept Shares Rise More Than 55% in 6 Months: Here's Why
CORT

Zacks

2 months ago

Corcept Shares Rise More Than 55% in 6 Months: Here's Why

Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock?
CORT

Zacks

2 months ago

Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock?

Corcept Therapeutics' (NASDAQ:CORT) Earnings Offer More Than Meets The Eye
CORT

Simply Wall St.

2 months ago

Corcept Therapeutics' (NASDAQ:CORT) Earnings Offer More Than Meets The Eye

CORT

Argus Research

2 months ago

CORT: Lowering target price to $59.00

Corcept Therapeutics Full Year 2024 Earnings: Misses Expectations
CORT

Simply Wall St.

2 months ago

Corcept Therapeutics Full Year 2024 Earnings: Misses Expectations

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
CORT

StockStory

2 months ago

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
CORT

StockStory

2 months ago

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

CORT

MT Newswires

2 months ago

Corcept Therapeutics Says New Drug Application for Cushing's Syndrome Treatment Filed by FDA

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
CORT

Business Wire

2 months ago

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT)
CORT

Zacks

2 months ago

3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT)

Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year?
CORT

Zacks

2 months ago

Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year?

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 48% Above Its Share Price
CORT

Simply Wall St.

2 months ago

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 48% Above Its Share Price

Why Corcept (CORT) Shares Are Sliding Today
CORT

StockStory

2 months ago

Why Corcept (CORT) Shares Are Sliding Today

CORT's Q4 Earnings and Revenues Fall Short of Estimates
CORT

Zacks

2 months ago

CORT's Q4 Earnings and Revenues Fall Short of Estimates

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
CORT

Zacks

2 months ago

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

CORT

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Corcept Therapeutics Inc Earnings Call

Corcept Therapeutics Inc (CORT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
CORT

GuruFocus.com

2 months ago

Corcept Therapeutics Inc (CORT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates
CORT

Zacks

2 months ago

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

CORT

Associated Press Finance

2 months ago

Corcept: Q4 Earnings Snapshot

CORT

MT Newswires

2 months ago

Corcept Q4 Net Income Lower, Revenue Rises; Sets Guidance

Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings
CORT

StockStory

2 months ago

Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update
CORT

Business Wire

2 months ago

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

CORT

Argus Research

2 months ago

CORT: Lowering target price to $64.00

Corcept (CORT) Q4 Earnings Report Preview: What To Look For
CORT

StockStory

2 months ago

Corcept (CORT) Q4 Earnings Report Preview: What To Look For

Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma Stock So Far in 2025
CORT

Insider Monkey

3 months ago

Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma Stock So Far in 2025

CORT

Argus Research

3 months ago

CORT: Raising target price to $76.00

Recursion Pharmaceuticals Stock Scores RS Ratings Over 90
CORT

Investor's Business Daily

3 months ago

Recursion Pharmaceuticals Stock Scores RS Ratings Over 90

Incyte Stock Sees Relative Strength Rating Rise To 71
CORT

Investor's Business Daily

3 months ago

Incyte Stock Sees Relative Strength Rating Rise To 71

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
CORT

Business Wire

3 months ago

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

3 US Growth Companies With High Insider Ownership Expecting Up To 22% Revenue Growth
CORT

Simply Wall St.

3 months ago

3 US Growth Companies With High Insider Ownership Expecting Up To 22% Revenue Growth

CORT

Argus Research

3 months ago

CORT: Raising target price to $70.00

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
CORT

Zacks

3 months ago

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?
CORT

Zacks

3 months ago

Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
CORT

Zacks

3 months ago

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

Zacks.com featured highlights include OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham
CORT

Zacks

3 months ago

Zacks.com featured highlights include OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham

All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy
CORT

Zacks

3 months ago

All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy

Buy These 5 Stocks With Recent Price Strength Amid a Volatile January
CORT

Zacks

3 months ago

Buy These 5 Stocks With Recent Price Strength Amid a Volatile January

Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes"
CORT

Zacks

4 months ago

Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes"

Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?
CORT

Zacks

4 months ago

Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?

Medical Stock Soars To Highs As Cortisol Screening Grows
CORT

Investor's Business Daily

4 months ago

Medical Stock Soars To Highs As Cortisol Screening Grows

CORT

Argus Research

4 months ago

CORT: Raising target price to $64.00

Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT)
CORT

Insider Monkey

4 months ago

Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years?
CORT

Insider Monkey

4 months ago

Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years?

CORT

Argus Research

4 months ago

CORT: What does Argus have to say about CORT?

Share on Social Networks: